Hyundai Pharmaceutical Co Ltd banner

Hyundai Pharmaceutical Co Ltd
KRX:004310

Watchlist Manager
Hyundai Pharmaceutical Co Ltd Logo
Hyundai Pharmaceutical Co Ltd
KRX:004310
Watchlist
Price: 8 640 KRW 0.93% Market Closed
Market Cap: ₩225.8B

Hyundai Pharmaceutical Co Ltd
PP&E Net

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Hyundai Pharmaceutical Co Ltd
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Hyundai Pharmaceutical Co Ltd
KRX:004310
PP&E Net
₩39B
CAGR 3-Years
11%
CAGR 5-Years
5%
CAGR 10-Years
2%
Yuhan Corp
KRX:000100
PP&E Net
₩638.7B
CAGR 3-Years
22%
CAGR 5-Years
14%
CAGR 10-Years
8%
SK Biopharmaceuticals Co Ltd
KRX:326030
PP&E Net
₩60.5B
CAGR 3-Years
44%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
PP&E Net
₩786.3B
CAGR 3-Years
-5%
CAGR 5-Years
-5%
CAGR 10-Years
7%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
PP&E Net
₩143.1B
CAGR 3-Years
18%
CAGR 5-Years
18%
CAGR 10-Years
9%
C
Caregen Co Ltd
KOSDAQ:214370
PP&E Net
₩125.4B
CAGR 3-Years
28%
CAGR 5-Years
16%
CAGR 10-Years
N/A
No Stocks Found

Hyundai Pharmaceutical Co Ltd
Glance View

Market Cap
225.8B KRW
Industry
Pharmaceuticals

Hyundai Pharmaceutical Co., Ltd. engages in the manufacturing and distribution of pharmaceutical products, health food drinks and medical equipment. The company is headquartered in Cheonan, Chungcheongnam-Do and currently employs 378 full-time employees. The firm mainly provides two categories of products: pharmaceuticals, including ophthalmological tablets, clopidogrel bisulfate, mirtazapine tablets and others, which are applied in the treatment of depressive disorder, hypertension, hemostatics and others, as well as healthcare food products, including vitamin products, calcium supplements and others. The company also provides dietary various beverages and medical equipment. The firm mainly distributes its products within domestic market. In addition, the Company also involves in the leasing business.

Intrinsic Value
4 426.18 KRW
Overvaluation 49%
Intrinsic Value
Price ₩8 640

See Also

What is Hyundai Pharmaceutical Co Ltd's PP&E Net?
PP&E Net
39B KRW

Based on the financial report for Aug 31, 2025, Hyundai Pharmaceutical Co Ltd's PP&E Net amounts to 39B KRW.

What is Hyundai Pharmaceutical Co Ltd's PP&E Net growth rate?
PP&E Net CAGR 10Y
2%

Over the last year, the PP&E Net growth was 4%. The average annual PP&E Net growth rates for Hyundai Pharmaceutical Co Ltd have been 11% over the past three years , 5% over the past five years , and 2% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett